Shield Therapeutics announces submission of a New Drug Application (NDA) for Feraccru® with the US Food and Drug Administration (FDA)

1 Oct 2018

Shield Therapeutics plc, today announces that it has received confirmation from the US FDA of its successful submission of an NDA for Feraccru®. For more details please see the press release below.

STX_NDA submission

Back to news

London, UK

16 Upper Woburn Place
Euston
London, WC1H 0AF

t+44 (0) 207 186 8500

einfo@shieldtx.com

Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500

einfo@shieldtx.com

Wollerau, Switzerland

Sihleggstrasse 23,
8832 Wollerau
Switzerland

t+41 (0) 435 080 781

einfo@shieldtx.com

Berlin, Germany

Oranienburger Str. 3
c/o Lambsdorff Rechtsanwälte PartGmbB
10178 Berlin
Germany

t+44 (0) 207 186 8500

einfo@shieldtx.com